News
Mixed outcomes for pharma in big week for FDA adcomms
There was good news for Johnson & Johnson at this week's ODAC meetings, but not for Roche, UroGen, and Pfizer.
News
UK trumpets £1bn investment plan from BioNTech
BioNTech has said it will commit up to £1bn in investment in the UK over the next decade, in what has been described as a "template" for the sector.
News
Pfizer snaps up PD-1/VEGF drug from China's 3SBio
Pfizer has joined the ranks of those developing cancer drugs that target PD-1 and VEGF, penning a $6bn licensing deal with China's 3SBio.
News
Japan follows UK in GSK's comeback tour for Blenrep
The revitalisation of GSK's blood cancer therapy Blenrep continues with a second approval, in Japan, as a second-line treatment for multiple myeloma.
News
Incyte's PD-1 drug brings immunotherapy to anal cancer
Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
